Risk Stratification in Older Intensively Treated Patients With AML.

Autor: Versluis J; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Metzner M; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom., Wang A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom., Gradowska P; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.; HOVON Foundation, Rotterdam, the Netherlands., Thomas A; Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom., Jakobsen NA; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom., Kennedy A; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom., Moore R; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom., Boertjes E; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Vonk CM; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Kavelaars FG; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Rijken M; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Gilkes A; School of Medicine, Cardiff University, Cardiff, United Kingdom., Schwab C; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Beverloo HB; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands., Manz M; Department of Hematology, University Hospital Zurich, Zurich, Switzerland., Visser O; Department of Hematology, Isala Hospital, Zwolle, the Netherlands., Van Elssen CHMJ; Maastricht University Medical Center, Maastricht, the Netherlands., de Weerdt O; Antonius Hospital, Nieuwegein, the Netherlands., Tick LW; Maxima Medical Center, Eindhoven, the Netherlands., Biemond BJ; Amsterdam UMC, Location AMC, Cancer Center Amsterdam, Amsterdam, the Netherlands., Vekemans MC; Cliniques Universitaires Saint-Luc, Brussels, Belgium., Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Harrison CJ; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom., Cook JA; Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom., Dennis M; The Christie NHS Foundation Trust, Manchester, United Kingdom., Knapper S; School of Medicine, Cardiff University, Cardiff, United Kingdom., Thomas I; Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom., Craddock C; Warwick Clinical Trials Unit, University of Warwick, Warwick, United Kingdom., Ossenkoppele GJ; Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Löwenberg B; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Russell N; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Valk PJM; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands., Vyas P; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Haematology, Oxford University Hospitals NHS Trust and Oxford Biomedical Centre, Oxford, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 04, pp. JCO2302631. Date of Electronic Publication: 2024 Sep 04.

Increased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?

Autor: Boerenkamp LS; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Pothast CR; Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands., Dijkland RC; Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands., van Dijk K; Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands., van Gorkom GNY; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., van Loo IHM; Medical Microbiology, Maastricht University Medical Center, Maastricht, The Netherlands., Wieten L; Department of Transplantation Immunology, Maastricht University Medical Center, Maastricht, The Netherlands., Halkes CJM; Hematology, Leiden University Medical Center, Leiden, The Netherlands., Heemskerk MHM; Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands., Van Elssen CHMJ; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.

Publikováno v: American journal of hematology [Am J Hematol] 2022 Dec; Vol. 97 (12), pp. E457-E461. Date of Electronic Publication: 2022 Sep 24.

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.

Autor: Tettero JM; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Al-Badri WKW; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Ngai LL; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Bachas C; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Breems DA; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium., van Elssen CHMJ; Department of Internal Medicine, Division of Hematology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Fischer T; Department of Hematology and Oncology, Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany., Gjertsen BT; Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway., van Gorkom GNY; Department of Internal Medicine, Division of Hematology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Gradowska P; The Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Data Center, Department of Hematology, Erasmus Medical Center (MC) Cancer Institute, Rotterdam, Netherlands., Greuter MJE; Department of Epidemiology and Data Science, Amsterdam Univerisity Medical Centers, location Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Griskevicius L; Hematology, Oncology, Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania., Juliusson G; Department of Hematology, Skanes University Hospital, Lund, Sweden., Maertens J; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium., Manz MG; Department of Medical Oncology and Hematology, University Hospital, Zurich, Switzerland.; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Pabst T; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.; Department of Medical Oncology, Inselspital, University Hospital, Bern, Switzerland., Passweg J; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.; Department of Hematology, University Hospital, Basel, Switzerland., Porkka K; Department of Hematology, Helsinki University Hospital Cancer Center, Helsinki, Finland., Löwenberg B; Department of Hematology, Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Janssen JJWM; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Cloos J; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Oct 10; Vol. 12, pp. 999822. Date of Electronic Publication: 2022 Oct 10 (Print Publication: 2022).

NK cell alloreactivity in acute myeloid leukemia in the post-transplant cyclophosphamide era.

Autor: Van Elssen CHMJ; Department of Internal Medicine, Division of Hematology, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Ciurea SO; Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1590-1598. Date of Electronic Publication: 2020 Sep 28.

Influence of Vitamin C on Lymphocytes: An Overview.

Autor: van Gorkom GNY; Division of Hematology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202AZ Maastricht, The Netherlands. gwendolyn.van.gorkom@mumc.nl., Klein Wolterink RGJ; Division of Hematology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202AZ Maastricht, The Netherlands. r.kleinwolterink@maastrichtuniversity.nl., Van Elssen CHMJ; Division of Hematology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202AZ Maastricht, The Netherlands. janine.van.elssen@mumc.nl., Wieten L; Department of Transplantation Immunology, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands. Lotte.wieten@maastrichtuniversity.nl., Germeraad WTV; Division of Hematology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202AZ Maastricht, The Netherlands. w.germeraad@maastrichtuniversity.nl., Bos GMJ; Division of Hematology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202AZ Maastricht, The Netherlands. gerard.bos@mumc.nl.

Publikováno v: Antioxidants (Basel, Switzerland) [Antioxidants (Basel)] 2018 Mar 10; Vol. 7 (3). Date of Electronic Publication: 2018 Mar 10.